Figure 3.
Cellular effects of ranibizumab (a), bevacizumab (b), pegaptanib (c), and aflibercept (d) on L929 cells. Cells shown are at Day 5 of various treatment concentrations (H&E staining, magnification ×1000).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.